Fixed-dose sofosbuvir/ledipasvir with or without ribavirin cures most genotype 1 patients, LONESTAR study
Matt Chris said
Nov 13, 2013
Thanks Jill & Lil Eddie
There is some very interesting parts of this study about Rav's at baseline and what happened with Rav's with extended treatment.
Here is the excerpt
"Seven of the nine people with NS5A resistance mutations and all 28 people with NS3/4A (protease) resistance mutations at baseline nevertheless achieved sustained response. One patient had evidence of the S282T mutation and multiple NS5A resistance mutations at the time of relapse at week 8. This individual was retreated with sofosbuvir/ledipasvir plus ribavirin for 24 weeks and went on to achieve SVR12."
My trial doctor made a big deal about this because he said "it surprised a lot of people"
So the world of treatment by DAA's has gotten a whole lot more complicated and interesting. Stay tuned their will be many turns in the road ahead.
matt
Cinnamon Girl said
Nov 12, 2013
Fixed-dose sofosbuvir/ledipasvir with or without ribavirin cures most genotype 1 hepatitis C patients, LONESTAR study shows
`At least 95% of newly treated people with genotype 1 hepatitis C and prior non-responders achieved sustained virological response using a fixed-dose combination of sofosbuvir plus ledipasvir, with or without ribavirin, according to findings from the LONESTAR study presented at the 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC. While response rates were high overall, the two relapsers in the trial were not taking ribavirin.`
`Eric Lawitz of the Texas Liver Institute reported results from the phase 2 LONESTAR study, which evaluated a fixed-dose combination pill containing Gilead Sciences' HCV polymerase inhibitor sofosbuvir (formerly GS-7977) plus the NS5A inhibitor ledipasvir (formerly GS-5885), taken with or without ribavirin for 8 or 12 weeks.`
Thanks Jill & Lil Eddie
There is some very interesting parts of this study about Rav's at baseline and what happened with Rav's with extended treatment.
Here is the excerpt
"Seven of the nine people with NS5A resistance mutations and all 28 people with NS3/4A (protease) resistance mutations at baseline nevertheless achieved sustained response. One patient had evidence of the S282T mutation and multiple NS5A resistance mutations at the time of relapse at week 8. This individual was retreated with sofosbuvir/ledipasvir plus ribavirin for 24 weeks and went on to achieve SVR12."
My trial doctor made a big deal about this because he said "it surprised a lot of people"
So the world of treatment by DAA's has gotten a whole lot more complicated and interesting. Stay tuned their will be many turns in the road ahead.
matt
Fixed-dose sofosbuvir/ledipasvir with or without ribavirin cures most genotype 1 hepatitis C patients, LONESTAR study shows
`At least 95% of newly treated people with genotype 1 hepatitis C and prior non-responders achieved sustained virological response using a fixed-dose combination of sofosbuvir plus ledipasvir, with or without ribavirin, according to findings from the LONESTAR study presented at the 64th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC. While response rates were high overall, the two relapsers in the trial were not taking ribavirin.`
`Eric Lawitz of the Texas Liver Institute reported results from the phase 2 LONESTAR study, which evaluated a fixed-dose combination pill containing Gilead Sciences' HCV polymerase inhibitor sofosbuvir (formerly GS-7977) plus the NS5A inhibitor ledipasvir (formerly GS-5885), taken with or without ribavirin for 8 or 12 weeks.`
Full article...
http://www.aidsmap.com/Fixed-dose-sofosbuvirledipasvir-with-or-without-ribavirin-cures-most-genotype-1-hepatitis-C-patients-LONESTAR-study-shows/page/2801641/
* With many thanks to Lil Eddie for posting this info on the ION-3 Clinical Trials thread...I`m reposting it here for anyone who missed it.
http://hepcfriends.activeboard.com/t53618592/ion-3-trial/#lastPostAnchor